Introduction {#Sec1}
============

Coronavirus disease-19 (COVID-19) is an ongoing pandemic with a progressively increasing number of cases and deaths worldwide. Resource allocation for critical cases is one of the challenging aspects of this pandemic, which warrants an urgent need to identify the patients at higher risk of severity and mortality. One study showed that patients with cerebrovascular diseases (CeVD) were associated with more severe infections \[[@CR1]\]. Similar to Severe Acute Respiratory Syndrome (SARS) virus, some studies suggest a possible neurotropic mechanism of SARS-CoV-2 virus which would provide a basis for neurological manifestations of COVID-19 \[[@CR2]\]. The virus may enter the cerebral circulation, and the interaction of viral spike proteins with ACE2 receptors expressed in the capillary endothelium in the brain might damage the blood--brain barrier \[[@CR3]\]. Several studies have been published on the epidemiological characteristics of COVID-19; however, data on patients with pre-existing CeVD are limited by a very small number of patients across these studies. In this article, we sought to carry out a pooled analysis of existing studies to evaluate the prevalence of CeVD and outcomes of COVID-19 patients with pre-existing CeVD.

Methods {#Sec2}
=======

Endpoints {#Sec3}
---------

The primary aim of this study was to evaluate prevalence and outcomes \[intensive care unit (ICU) admission, mechanical ventilation, and mortality\] of COVID-19 hospitalized patients with pre-existing cerebrovascular disease or stroke. Pre-existing cerebrovascular disease was defined as history of ischemic or transient ischemic attack irrespective to severity or disability status. COVID-19 confirmation was evaluated by combined findings of RT-PCR, serology, symptoms, and MRI chest in majority of those studies. The secondary aim of this study is to evaluate composite poor outcome associated with COVID-19 hospitalized patients with pre-existing cerebrovascular disease or stroke. The composite poor outcome is defined as intensive care unit (ICU) admission, oxygen saturation \< 90%, invasive mechanical ventilation (IMV) utilization, severe disease, and in-hospital mortality.

Search strategy and selection criteria {#Sec4}
--------------------------------------

A systematic review was performed using MOOSE guidelines \[[@CR4]\]. We searched PubMed, Web of Science, and Scopus for observational studies that described characteristics of COVID-19 from December 1, 2019 to April 30, 2020 following keyword/MESH terms: ((COVID-19 \[Title/Abstract\]) OR coronavirus \[Title/Abstract\]) OR SARS-CoV-2 \[Title/Abstract\] OR 2019-nCoV \[Title/Abstract\]. All studies describing epidemiology of COVID-19 were included. Literature other than observational studies, non-English literature, non-full text, and animal studies were excluded. Flow diagram of literature search and study selection process is described in Supplemental file 1.

Study selection {#Sec5}
---------------

Abstracts were reviewed, and articles were retrieved only if they mention CeVD or stroke as one of the pre-existing comorbidities. UP and PM independently screened all identified studies and assessed full texts to decide eligibility. Any disagreement was resolved through discussion with other reviewers (DS and AP).

Data collection {#Sec6}
---------------

From the included studies, data relating to patient characteristics, outcomes of interest, and medical history of CeVD (as comorbidity) were collected using prespecified data collection forms by two authors (UP and PM), and discrepancies were solved by a discussion with DS. The following study characteristics were extracted: publication year, country of origin, sample size, age, history of CeVD as comorbidity, and outcomes. For secondary aim evolution, data of composite outcomes (poor vs non-poor) were collected.

Assessment of risk of bias {#Sec7}
--------------------------

The Newcastle--Ottawa Quality Assessment Scale \[[@CR5]\] and Cochrane Collaboration's tool \[[@CR6]\] were used to evaluate the quality of the included studies and the risk of bias.

Statistical analysis {#Sec8}
--------------------

Primary aim was evaluated using comprehensive meta-analysis software, we calculated pooled prevalence, 95% confidence interval (95% CI), and weights for CeVD and outcomes (events). Meta-regression was performed to evaluate the effects of pre-existing CeVD on outcomes of COVID-19 patients. Correlation coefficient (*r*) and estimated odds ratio (OR) \[*e*\^coefficient\] between pre-existing CeVD and outcomes with corresponding 95% CI and quantifying magnitude of the relationship were pooled using a random-effects model. The proportion of total between-study variance explained by the model identified using analogous index (*R*^2^) and statistical heterogeneity across studies was reported using the *I*^2^ statistics. Age-adjusted meta-regression was conducted to study the impact on incremental age. Review Manager version 5.4 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) was used to evaluate secondary aim. The Maentel--Haenszel formula with random-effects model was used to calculate OR along with its 95% CI to describe the relationship of pre-existing CeVD and composite outcomes of COVID-19 patients in each study. The *I*^2^ statistic of \> 75% was considered significant heterogeneity. *p* \< 0.05 was considered significant. Sensitivity analysis was also performed using the "leave-one-out method" to probe sources of heterogeneity.

Results {#Sec9}
=======

As of April 30, 2020, we included 11 observational studies with 4987 confirmed cases of COVID-19 patients detailing pre-existing CeVD. Of those 11 studies, 7 studies have reported ICU admissions (623/3901), and 8 studies have reported mechanical ventilation utilization (384/2196) and deaths (540/4240). Pooled prevalence of pre-existing CeVD comorbidity was 4.4% \[95% CI 2.9--6.5%; *p* \< 0.001; 244/4987 patients\], ICU admission was 19.3% \[95% CI 11.0--31.7%; *p* \< 0.001; 623/3901 patients\], mechanical ventilation was 22.9% \[95% CI 11.5--40.4%; *p* = 0.004; 384/2196 patients\], and mortality was 14.3% \[95% CI 7.2--26.4%; *p* \< 0.0001; 540/4240 patients\] (Table [1](#Tab1){ref-type="table"}).Table 1Study characteristics and pooled prevalence of pre-existing cerebrovascular disease and outcomesStudySample sizeDefinition of pre-existing cerebrovascular diseaseAge\
Mean or median (years)Sex (male %)Pre-existing cerebrovascular disease \[*n*; pooled prevalence (%) (95% CI)\*; weight (%)^†^\]\
Total study (*n*) = 11ICU admission \[events; event rate (%) (95% CI)\*; weight (%)^†^\]\
Total study (*n*) = 7Mechanical ventilation \[events; event rate (%) (95% CI)\*; weight (%)^†^\]\
Total study (*n*) = 8Mortality \[events; event rate (%) (95% CI)\*; weight (%)^†^\]\
Total study (*n*) = 8Composite outcomes (poor outcomes vs non-poor outcome)Guan et al. \[[@CR18]\]1099Cerebrovascular disease4757.9615; 1.4 (0.8--2.3); 10.6655; 5 (3.9--6.5); 17.8767; 6.1 (4.8--7.7); 13.4215; 1.4 (0.8--2.3)4/173 Severe vs 11/926 no-severeWang et al. \[[@CR19]\]138Cerebrovascular disease5654.357; 5.1 (2.4--10.3); 8.9836; 26.1 (19.4--34.0); 17.3617; 12.3 (7.8--18.9); 12.936; 4.3 (2.0--9.3)6/36 ICU vs 1/102 non-ICUXu et al. \[[@CR20]\]62Cerebrovascular disease4156.451; 1.6 (0.2--10.6); 3.401; 1.6 (0.2--10.6); 6.971; 1.6 (0.2--10.6); 7.650; 0.8 (0.0--11.5)N/AZhang et al. \[[@CR21]\]140Stroke5750.713; 2.1 (0.7--6.4); 6.60N/AN/AN/A2/58 Severe vs 1/82 non-severeYang et al. \[[@CR22]\]52Cerebrovascular disease59.767.317; 13.5 (6.6--25.6); 8.7452; 99.1 (86.6--99.9); 4.3237; 71.2 (57.5--81.8)^a^; 12.6832; 61.5 (47.8--73.7)^d^7/32 Non-survivors vs 0/20 survivorsMo et al. \[[@CR23]\]155Cerebrovascular diseases5455.487; 4.5 (2.2--9.2); 8.99N/A36; 23.2 (17.2--30.5); 13.22N/A7/85 Refractory pneumonia vs 0/70 general pneumoniaWu et al. \[[@CR24]\]201Nervous system disease5163.687; 3.5 (1.7--7.1); 9.0253; 26.4 (20.7--32.9); 17.6967; 33.3 (27.2--40.1); 13.3644; 21.9 (16.7--28.1)N/AWang et al. \[[@CR25]\]339Cerebrovascular disease6948.9721; 6.2 (4.1--9.3); 11.07N/A80; 23.6 (19.4--28.4); 13.4265; 19.2 (15.3--23.7)10/65 Dead vs 11/274 survivalRuan et al. \[[@CR26]\]150Cerebrovascular disease586812; 8.0 (4.6--13.6)41; 27.3 (20.8--35.0); 17.4779; 52.7 (44.7--60.5)^b^; 13.3268; 45.3 (37.6--53.4)^e^7/68 Died vs 5/82 dischargedQin et al. \[[@CR27]\]452Cerebrovascular disease585211; 2.4 (1.4--4.3); 10.07N/AN/AN/A8/286 Severe vs 3/166 non-severeParanjpe et al. \[[@CR28]\]2199Stroke6558.8153; 7.0 (6.0--8.1); 12.34385; 17.5 (16.0--19.2); 18.33N/A310; 14.1 (12.7--15.6)32/310 In-hospital mortality vs 40/768 dischargedTotal4987244/4987; 4.4 (2.9--6.5); 100623/3901; 19.3 (11.0--31.7); 100384/2196; 22.9 (11.5--40.4); 100540/4240; 14.3 (7.2--26.4)\*Statistically significant at *p* \< 0.001 except for (a) *p* = 0.003, (b) *p* = 0.514, (c) *p* = 0.004, (d) *p* = 0.099 and (e) *p* = 0.254^†^Weight (%) = relative weight (random)^\#^Severe cases (World Health Organization and the National Health Commission of China): respiratory distress, respiratory rate ≥ 30 breaths/min; SpO~2~ ≤ 93% at rest; and PaO~2~/FIO~2~ ≤ 300. Patients with \> 50% lesion progression within 24--48 h. Critical/extremely severe cases: if they have one of the following: respiratory failure requiring mechanical ventilation, shock, and other organ failure requiring ICU treatment

Meta-regression {#Sec10}
---------------

Meta-regression random effects models quantified the study level impact of pre-existing CeVD in COVID-19 patients on ICU admission, mechanical ventilation utilization, and mortality. Amongst COVID-19 patients with pre-existing CeVD, the unadjusted meta regression models showed strong association with ICU admission \[*r*: 0.43; OR: 1.54; 95% CI 1.25--1.62; *I*^2^: 94.5%; *p* = 0.0001\], mechanical ventilation \[*r*: 0.28; OR: 1.32; 95% CI: 1.13--1.55; *I*^2^: 91.3%; *p* = 0.005\], and mortality \[*r*: 0.37; OR: 1.45; 95% CI 1.22--1.72; *I*^2^: 95.9%; *p* \< 0.0001\] (Table [2](#Tab2){ref-type="table"}).Table 2Meta-regression showing association of pre-existing cerebrovascular disease and outcomeCorrelation coefficient between CeVD and outcomes (95% CI); *p* valueOdds ratio *e*\^coefficient (95%CI)Quantifying magnitude of the relationship ln(outcome rate) = intercept + m(*X*)Analogous index (*R*^2^)Heterogeneity\* *I*^2^ (%); Cochran's Qmodel; Tau^2^ unexplainedICU admission (unadjusted)0.43 (0.22--0.65); 0.00011.54 (1.25--1.62)− 3.65 + 0.43 (CeVD%)0.0794.46; 15.48; 0.57ICU admission (age-adjusted)0.60 (0.22--0.99); 0.00211.82 (1.25--2.69)− 0.18 + 0.60 (CeVD%) + 0.60 (age in years)0.0093.82; 15.13; 0.78Mechanical ventilation (unadjusted)0.28 (0.12--0.44); 0.00051.32 (1.13--1.55)− 2.65 + 0.28 (CeVD%)0.3891.28; 12.19; 0.40Mechanical ventilation (age-adjusted)0.29 (0.09--0.49); 0.00381.33 (1.09--1.63)− 3.53 + 0.29 (CeVD%) + 0.01 (age in years)0.5793.43; 14.74; 0.57Mortality (unadjusted)0.37 (0.20--0.54); \< 0.00011.45 (1.22--1.72)− 4.30 + 0.37 (CeVD%)0.4095.93; 18.00; 0.65Mortality (age-adjusted)0.35 (0.13--0.57); 0.00181.42 (1.14--1.77)− 5.01 + 0.35 (CeVD%) + 0.02 (age in years)0.3296.11; 16.46; 0.73Meta-regression models are based on random effects*X* pre-existing cerebrovascular disease\*Statistically significant at *p* \< 0.001

Similarly, in age-adjusted meta-regression analysis, pre-existing CeVD among COVID-19 patients was associated with higher estimated odds of ICU admission \[*r*: 0.60; OR: 1.82; 95% CI 1.25--2.69; *I*^2^: 93.8%; *p* = 0.0021\], mechanical ventilation \[*r*: 0.29; OR: 1.33; 95% CI 1.09--1.63; *I*^2^: 93.4%; *p* = 0.0038\], and mortality \[*r*: 0.35; OR: 1.42; 95% CI 1.14--1.77; *I*^2^: 96.1%; *p* = 0.0018\]. Figure [1](#Fig1){ref-type="fig"}a--c suggests a significant increase between log odds of poor outcomes and pre-existing CeVD in COVID-19 patients. Sensitivity analysis showed that the removal of any single study did not change the significance of the results. Additionally, overall studies had moderate risk of bias (Supplemental file 2). The heterogeneity analysis of the age-adjusted models of ICU admission, mechanical ventilation, and mortality showed 93.8%, 93.4% and 96.1% dispersion observed between studies, respectively, and 0%, 57% and 32% of such variance was explained by the models, respectively.Fig. 1**a** Cerebrovascular disease and ICU admission. **b** Cerebrovascular disease and mechanical ventilation. **c** Cerebrovascular disease and mortality

Meta-analysis {#Sec11}
-------------

A total of 9 studies reported data on pre-existing CeVD and binary composite outcomes giving a total sample size of 3603 COVID-19 hospitalizations, the pooled prevalence of pre-existing CeVD was 4.3% (155/3603). In patients with poor outcomes, the pooled prevalence of pre-existing CeVD was 7.46% (83/1113). Meta-analysis of all nine studies showed that COVID-19 patient with pre-existing CeVD had higher odds of poor outcomes compared to better outcomes with a pooled OR of 2.67 (95% CI 1.75--4.06; *p* = 0.03), with minimal heterogeneity between studies (*I*^2^ = 12%; Tau^2^ = 0.05; Chi^2^ = 9.10; *p* ≤ 0.00001) (Fig. [2](#Fig2){ref-type="fig"}). Leave-one-out method sensitivity analysis did not change odds ratio.Fig. 2Forest plot of pre-existing cerebrovascular disease and composite outcome

Discussion {#Sec12}
==========

In our analysis, pooled prevalence of pre-existing CeVD was \~ 4.4% among confirmed cases of COVID-19. The pooled prevalence of pre-existing CeVD was 7.46% in among COVID-19 patients with poor outcomes. We found that pre-existing CeVD was significantly associated with increased risk of ICU admission and mechanical ventilation utilization in patients with COVID-19. In meta-analysis, pre-existing CeVD had 2.67-fold high risk of poor outcomes. Our findings are supported by recently published pooled analysis, where authors have reported that CeVD was associated with approximate 2.5-fold increased disease severity in COVID-19 patients \[[@CR7]\]. Furthermore, we found a significant incremental correlation between pre-existing CeVD and mortality in COVID-19 patients. CeVD is associated with high mortality, morbidity, and increased healthcare costs in USA \[[@CR8]\]. Previous studies have reported that SARS and Middle East Respiratory Syndrome patients with pre-existing CeVD were not only at higher risk of poor outcomes, but also increased health care utilization \[[@CR9], [@CR10]\]. The exact pathophysiology behind role of pre-existing CeVD and poor outcome is still to be determined but such patients are at high risk due to underlying concurrent conditions such as old age, hypertension, cardiovascular disorders like arrythmia, diabetes, low immunity-related \[[@CR11]\] COVID-19 severity, etc. Such patients are also at risk of developing cardio-embolic events \[[@CR12]\] secondary to viral and bacterial infection or new cerebrovascular events secondary to thrombotic microangiopathy \[[@CR13], [@CR14]\], hypercoagulability leading to macro- and micro-thrombi formation in the vessels, hypoxic injury, disruption of the blood and blood brain barrier \[[@CR15]\].

The national data from RAPID AI, a commercially available automated acute stroke screening software, have shown 39% reduction in acute emergency department (ED) stroke evaluation during a 29-day pre-pandemic period in February 2020 to a 2-week stretch of March 26 to April 8 in 856 hospitals across the USA \[[@CR16]\]. This reduction may be explained by enforced social distancing practice due to pandemic. Such behavior may exclude asymptomatic or mildly symptomatic COVID-19 individuals from minor stroke symptom evaluation in ED who potentially could be at higher risk of stroke recurrence and poor outcome. Therefore, in the setting of limited healthcare resources in the current COVID-19 pandemic, identifying high risk patients will help to prioritize and individualize treatment protocols based on severity of pre-existing disease and predominant organ involvement \[[@CR17]\].

Strength and limitations {#Sec13}
========================

To our knowledge, this is the large population study that shows association between pre-existing CeVD and outcomes, especially mortality. Our findings may provide early insights into designing models for early identification of high-risk patients and prioritizing their treatment based on disease severity, which will help in prudent use of limited healthcare resources during this pandemic. A limitation of this study is missing details on type of CeVD or stroke severity, stroke disability (NIHSS or mRS), types, and medications. In addition, we have analyzed only COVID-19 hospitalized patients, so prediction of outcomes amongst COVID-19 positive with mild-to-moderate symptoms are unknown. Due to non-identical effects being estimated in studies analyzed in our meta-regression, our study has high heterogeneity which we tried to justify using random-effects model and sensitivity analysis. Moreover, meta-regression analysis will always be subject to the risk of ecological fallacy, as we attempt to make inferences about individuals using study-level information. However, our meta-analysis had no significant heterogeneity and also showed higher odds of poor outcomes in COVID-19 patients with preexisting CeVD. More observational studies, adjusted for risk factors and comorbidities with larger sample sizes dedicated to evaluating stroke burden, are needed to confirm our findings.

Conclusion {#Sec14}
==========

We found that COVID-19 patients with preexisting CeVD have poorer outcomes including increased ICU admission, mechanical ventilation utilization and mortality. However, large observational studies with reported outcomes are needed to validate these findings and evaluate the role of COVID-19 in developing new CeVD and stroke due to its pro-inflammatory and hypercoagulation states. Despite the limitations of our study, we advocate that clinicians should take extra precautions for patients with a history of cerebrovascular diseases during the ongoing pandemic.
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